Rituximab in Refractory Myasthenia Gravis: Experience in a Single Healthcare Center in Mexico

Background: Ten to fifteen percent of patients with myasthenia gravis (MG) have treatment-refractory disease. In short series and case reports, rituximab has proven to be effective in refractory MG. Methods: A retrospective, longitudinal study was conducted. Recruitment was performed in an MG cohort...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cureus
Huvudupphovsmän: López-Hernández, Juan Carlos, Galnares-Olalde, Javier A, Gómez-Figueroa, Enrique, Jorge de Sarachaga, Adib, Vargas-Cañas, Edwin Steven
Materialtyp: Artigo
Språk:Inglês
Publicerad: Cureus 2021
Ämnen:
Neurology
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7946608/
https://ncbi.nlm.nih.gov/pubmed/33728176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.13226
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk